Tycel J. Phillips, MD
Adding the BTK inhibitor acalabrutinib (Calquence) to bendamustine and rituximab (Rituxan; BR) induced high overall response rates (ORRs) in both treatment-naïve and relapsed/refractory patients with mantle cell lymphoma (MCL), according to results from a phase Ib trial presented at the 2018 ASH Annual Meeting.
Findings from the ongoing, open-label study showed a 94% (n = 17) ORR among 18 treatment-naïve patients, including a complete response (CR) rate of 72% (n = 13) and a partial response (PR) rate of 22% (n = 4). The ORR was 85% (n = 17) among 20 relapsed/refractory patients, including a CR rate of 65% (n = 13) and a PR rate of 20% (n = 4). There was also 1 patients with stable disease in the relapse/refractory subgroup.
“Obviously, this is a small study, but the combination looks safe and effective,” said study investigator Tycel Phillips, MD, who presented the data at ASH.
... to read the full story